Watch this recent chat to learn how Kaiser Permanente's integrated care model advances HIV care and treatment.
Colin Fields, MD, chief of HIV and PrEP at Washington Permanente Medical Group, calls for more HIV awareness among young adults, suggesting prevention messages spread through social media.
Stephen Parodi, MD, associate executive director of The Permanente Medical Group and national infectious disease leader for Kaiser Permanente, spoke with CBSN recently about why trials with remdesivir and other drugs matter. CBSN is the CBS News 24/7 digital streaming service.
A recent article in The New York Times examines an that doctors can use to assess patient risk for H.I.V and recommend a daily pill to prevent infection – a strategy referred to as PrEP. The idea to use data from electronic health records to determine if patients are at high risk for H.I.V. infection was borne from researchers at Kaiser Permanente Division of Research in Northern California and Harvard.
An algorithm developed by Kaiser Permanente researchers in Northern California could refer more at-risk patients for the preventive medication PrEP.
The article reported that resistance develops in two drugs used in PrEP because conventional HIV treatment uses three drugs.